Embecta Corporation (EMBC, Financial) was discussed in Keeley Teton's Small Cap Dividend Value Fund 1st-Quarter Commentary 2024 Q1 as one of the fund's biggest detractors. The company, a spin-off from Becton Dickinson, focuses on diabetes equipment but faces challenges in its growth strategy and market competition.
"Embecta shares were weak in the first quarter after the firm topped expectations in its fiscal first-quarter earnings release but raised full-year earnings guidance by less than the amount of the first quarter outperformance. In addition, the continued growth in the number of prescriptions issued for weight-loss drugs like Ozempic and Wegovy constrained investor sentiment toward companies like Embecta that are tied to growth in the number of patients with diabetes. Finally, some investors have expressed concerns about Embecta's decision to pursue growth in the form of a patch pump and the capital that the firm would need to devote to commercialize such a product." — Keeley Teton's Small Cap Dividend Value Fund Q1 2024 Fund Letter
Read full letter at gurufocus Keeley Teton's Small Cap Dividend Value Fund 1st-Quater Commentary 2024 Q1 page.
